Literature DB >> 25810972

Guillain-Barré syndrome presenting as Bell's palsy with crossed hemiparesis.

Vivek Chauhan1, G Sharma1, B S Rana1, V Jearth1, J Sandhu1.   

Abstract

Entities:  

Year:  2015        PMID: 25810972      PMCID: PMC4366836          DOI: 10.4103/2229-5151.152352

Source DB:  PubMed          Journal:  Int J Crit Illn Inj Sci        ISSN: 2229-5151


× No keyword cloud information.
Dear Editor, The rare variants of Guillain–Barré syndrome (GBS) are Miller–Fisher and Bickerstaff's brainstem encephalitis, and facial diplegia.[1] GBS can very rarely present as crossed hemiparesis, which occurred in our case. A 45-year-old female presented with left-sided Bell's palsy [Figure 1a] for 1 day with right-sided hemiparesis. The reflexes were diminished bilaterally and plantars were mute. First possibility in this case was a posterior circulation stroke, but her MRI brain ruled out any infarct or hemorrhage. On 2nd day, she developed quadriparesis with facial diplegia [Figure 1b], dysphagia, and bulbar palsy. Now we could make a confident diagnosis of GBS and cerebrospinal fluid (CSF) examination also showed albumino-cytological dissociation (proteins 259 mg/dl and total leukocyte count of 4 cells/mm3). She was treated with intravenous immunoglobulins and a month later she came back walking without support and facial diplegia was also improving [Figure 1c and d]. To conclude, GBS can very rarely present as Bell's palsy with crossed hemiparesis.
Figure 1

(a) Bell's palsy on left side at presentation. (b) Facial diplegia on 2nd day of admission. (c) Patient able to close both eyelids after 1 month. (d) Nasolabial furrow on right side at 1 month, left side is still weak

(a) Bell's palsy on left side at presentation. (b) Facial diplegia on 2nd day of admission. (c) Patient able to close both eyelids after 1 month. (d) Nasolabial furrow on right side at 1 month, left side is still weak
  1 in total

1.  Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases.

Authors:  M Mori; S Kuwabara; T Fukutake; T Hattori
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-05       Impact factor: 10.154

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.